IPO Traffic: Week Ending Sept. 19, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
Exagen Diagnostics (EXDX) Leerink Partners/ Baird       $69.00 n.a.
Hanson Building Products (TBA) BofA Merrill Lynch/ BNP PARIBAS/ Deutsche Bank Securities   $100.00 n.a.
NeuroDerm, Ltd. (NDRM) Jefferies/ Cowen and Company       $65.00 n.a.
Proteon Therapeutics (PRTO) Stifel/ JMP Securities       $69.00 n.a.
Sientra (SIEN) Piper Jaffray/ Stifel       $86.25 n.a.
Sky Solar Holdings (SKYS) FBR/ Cowen and Company       $100.00 n.a.
Tantech Holdings Ltd. (TANH) Newbridge Securities Corporation 1.60 $4.00 $6.00 $8.00 n.a.
Triumph Bancorp  (TBK) Sandler O’Neill & Partners/ Evercore Group     $100.00 n.a.
             
Postponed            
rEVO Biologics (RBIO) Piper Jaffray/ Guggenheim Securities 3.60 $13.00 $15.00 $50.40 1-Star
             
             
Withdrawn            
Isola Group (ISLA) UBS Investment Bank/ Piper Jaffray       $100.00 1-Star
Live Oak Bancshares  (LOB) Keefe, Bruyette & Woods (A Stifel Company)     $86.25 n.a.
Microlin Bio (MCLB) (u) Brean Capital/ Sunrise Securities 5.50 $4.50 $5.50 $27.50 1-Star
u = unit offering            
             
New Terms            
Antero Midstream Partners LP  (AM) Barclays/ Citigroup/ Wells Fargo Securities     $750.00 n.a.
Calithera Biosciences  (CALA) Citigroup/ Leerink Partners/ Wells Fargo Securities/ JMP Securities 6.00 $13.00 $15.00 $84.00 n.a.
Civitas Therapeutics (CVTS) J.P. Morgan/ BofA Merrill Lynch 4.00 $14.00 $16.00 $60.00 2-Stars
CONE Midstream Partners LP  (CNNX) Wells Fargo Securities/ BofA Merrill Lynch/ Baird 17.50 $19.00 $21.00 $350.00 2-Stars
Dermira  (DERM) Citigroup/ Leerink Partners 5.35 $14.00 $16.00 $80.25 n.a.
Medley Management  (MDLY) Goldman Sachs/ Credit Suisse 6.00 $20.00 $22.00 $126.00 2-Stars
Vantage Energy (VEI) Barclays/ Goldman Sachs 23.55 $24.00 $27.00 $600.53 1-Star
Vivint Solar  (VSLR) Goldman Sachs/ BofA Merrill Lynch/ Credit Suisse 20.60 $16.00 $18.00 $350.20 n.a.
VWR Corp (VWR) BofA Merrill Lynch/ Goldman Sach/ J.P. Morgan 25.53 $22.00 $25.00 $600.00 n.a.
Wayfair  (W) Goldman Sachs/ BofA Merrill Lynch/ Citigroup 11.00 $25.00 $28.00 $291.50 n.a.
             
IPOs Priced Lead Shares Amount Offer Close %
Week of Sept. 15, 2014 Manager(s) Offered Raised Price 9/19/14 Change
Alibaba Group Holding  (BABA) Credit Suisse/ Deutsche Bank Securities/ Goldman Sachs/ J.P. Morgan/ Morgan Stanley/ Citi 320.10 $21,766.87 $68.00 $93.89 38.07%
Tokai Pharmaceuticals  (TKAI) BMO Capital Markets/ Stifel/ William Blair 6.48 $97.20 $15.00 $18.39 22.60%
Civitas Solutions  (CIVI) Barclays/ Jefferies/ BofA Merrill Lynch/ UBS Investment Bank 11.70 $198.90 $17.00 $16.49 -3.00%
ProQR Therapeutics B.V.  (PRQR) Leerink Partners/ Deutsche Bank Securities 7.50 $97.50 $13.00 $16.37 25.92%
Foamix Ltd.   (FOMX) Barclays/ Cowen and Company 6.70 $40.20 $6.00 $6.15 2.50%

The IPO Buzz: Alibaba and the Road to Glory

Alibaba on the Turnpike
So far, the Alibaba IPO has been more traditional.
  • On May 6, 2014, the company filed for an IPO to raise $1 billion.
  • On Sept. 5, the company filed an amendment to offer 320.1 million American Depositary Shares at US$60 to US$66 each. The company expects to offer 123.1 million shares and selling shareholders plan to offer 197 million shares. The offering would raise US$20.2 billion, from the mid-point of its price range – making it the largest IPO ever.     
  • The pricing date was set for Thursday, Sept. 18, and the IPO is expected to trade on the New York Stock Exchange on Friday, Sept. 19.
An IPO of this size attracts a lot of talk, the latest being: The “book” accepting indications of interest is said to be closing early; the deal is reportedly well oversubscribed; investors can expect Alibaba to be priced above the high end of its range; various research providers rate the stock as a “buy” and some see an evaluation of US$100 per share for the stock.
 
Facebook’s Winding Road
The buildup to Facebook’s IPO was one of optimism marked by numerous updated amendments.
  • On Feb. 1, 2012, Facebook filed for an IPO to raise $5 billion.
  • On May 3, 2012, the company filed an amendment to offer 337.4 million shares at $28 to $35 each. At that price range, the deal would raise about $10.6 billion. The company was expected to offer 180 million shares and selling shareholders were expected to offer 157.4 million shares.
  • On May 14, 2012, an amendment was filed, increasing the proposed price range to $34 to $38, up from $28 to $35 per share.
  • On May 16, 2012, another amendment was filed, increasing the number of shares to 412.2 million, up from 337.4 million shares. The company was expected to offer 180 million shares and selling shareholders to offer 241.2 million shares, up from 157.44 million shares.
  • On Thursday, May 17, 2012. the deal was priced at 421 million shares at $38 each, on the high end of its latest price rang. It raised $16 billion.
  • On Friday, May 18, 2012, the deal was set to open on the NASDAQ Stock Market and things went badly wrong. Reportedly glitches developed in the trading system and caused delays in the opening and delays in execution reports getting back to investors and traders. Facebook’s trading became chaotic. The official opening price was $42.05, it sold as high as $45, as low as $38 and closed at $38.23.
  • Monday, May 21, 2012, turned out to be another nightmare. Facebook opened at $36.53, down $1.70 from the previous close, sold as high as $36.66, as low as $33 and closed at $34.03, down nearly $4 per share from its offering price.
Google’s Road Less Traveled
The Google IPO came to market in what is called a Dutch auction. This method is used by the U.S. Treasury in offering debt securities to raise money. In the IPO market, qualified investors submit the number of shares they wish to buy and at what price. The underwriters or agents collect bids and the clearing price is determined by the highest price it takes to sell all the shares. Under these circumstances, the IPO should trade around its initial offering price. The reason is simple: If all the investors willing to pay more for the IPO in the aftermarket get their orders filled in the Dutch auction, there will be no orders to bid up the stock in the aftermarket.
  • On April 29, 2004, Google filed for an IPO to raise $2.7 billion.
  • On July 26, 2004, the company filed an amendment to offer 24.6 million shares at $108 to $135 each. At that price range, the deal would raise about $3 billion. The company was expected to offer 14.1 million shares and selling shareholders to offer 10.5 million shares.
  • On Aug. 9, 2004, the company filed an amendment to offer 25.7 million shares at $108 to $135 each. At that price range, the deal would raise about $3.1 billion. The company was expected to offer 14.1 million shares and selling shareholders to offer 11.6 million shares.
  • On Aug. 18, 2004, the company filed an amendment to offer 19.6 million shares at $85 to $95 each. At that price range, the deal would raise about $1.76 billion. The company was expected to offer 14.1 million shares and selling shareholders to offer 5.46 million shares.
  • On Aug. 19, 2004, the company priced 19.6 million shares at $85 each. The deal raised $1.7 billion.
  • On Aug. 20, 2004, Google opened at $101.48, sold as high as $109.08, as low as $95.96 and closed its opening day at $100.35, UP $15.35 from its initial offering price.
Google’s clearing price was never reported nor was the size of allocations for the winning bids. The word around the Street was winning bids got about 75 percent of their indications of interest. That left about 25 percent of the orders on the table to be filled in the open market once the IPO started trading.  
 
This leads to deeper research for an explanation. Underwriters left wiggle room to “adjust” the offering price below the clearing price. Here is a clip from Google’s final prospectus: “The initial public offering price will be determined by the underwriters and us (Google) after the auction closes. We intend to use the auction clearing price as the principal factor to determine the initial public offering price and, therefore, to set an initial public offering price that is near or equal to the clearing price. However, we and our underwriters have the ability to set an initial public offering price that is below the clearing price.”
 
In Europe, the IPO Dutch auction has been used for decades. They call this tactic a “dirty Dutch auction.”
 
Looking into the week of Sept. 22, 2014, the calendar has five deals with bankers planning to raise about $4.8 billion. But more names could pop onto the calendar by the time that Monday, Sept. 22, rolls around.
 
Stay tuned.
 
Disclosure: Neither the author nor anyone else on the IPOScoop.com staff has a position in any stocks mentioned, nor do we trade or invest in IPOs. The author and IPOScoop.com staff do not issue advice, recommendations or opinions.
 

IPO Traffic: Week Ending Sept. 12, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
Arysta LifeScience plc  (ARYS) Morgan Stanley/ J.P. Morgan       $100.00 n.a.
Dave & Buster’s Entertainment  (PLAY) Jefferies/ Piper Jaffray       $100.00 n.a.
Energy & Exploration Partners (ENXP) Citigroup/ Credit Suisse/ RBC Capital Markets     $400.00 n.a.
Euronav NV (EURN ) Deutsche Bank Securities       $100.00 n.a.
Fifth Street Asset Management  (FSAM) Morgan Stanley/ J.P. Morgan/ Goldman Sachs/ RBC Capital Markets/ Credit Suisse/ SMBC Nikko $200.00 n.a.
Freshpet (TBA) Goldman Sachs/ Credit Suisse       $100.00 n.a.
Israel Corporation (ICL) Morgan Stanley/ Barclays/ Deutsche Bank Securities/ Goldman Sachs/ BMO Capital Markets 63.00 $7.41 $7.41 $466.83 n.a.
Kolltan Pharmaceuticals (KLTN) Leerink Partners/ Stifel       $86.25 n.a.
Mevion Medical Systems (MEV) Jefferies/ Leerink Partners       $69.00 n.a.
Performance Food Group  (TBA) Credit Suisse/ Barclays/ Wells Fargo Securities/ Morgan Stanley $100.00 n.a.
PRA Health Sciences  (PRAH) Jefferies/ Citigroup/ KKR/ UBS Investment Bank/ Credit Suisse/ Wells Fargo Securities $375.00 n.a.
Virobay (VBAY) Piper Jaffray/ JMP Securities       $50.00 n.a.
Xenon Pharmaceuticals  (XENE) Jefferies/ Wells Fargo Securities       $51.75 n.a.
n.a. (not available)            
             
Postponed            
None            
             
Withdrawn            
None            
             
New Terms            
AAC Holdings  (AAC) William Blair/ Raymond James       $75.00 n.a.
Anchor BanCorp Wisconsin (ABCW) Sandler ONeill & Partners/ Baird       $10.00 n.a.
Atento S.A.   (ATTO) Morgan Stanley/ Credit Suisse/ Itaú BBA 14.63 $19.00 $22.00 $299.81 n.a.
Capnia  (CAPNU) Maxim Group LLC 1.85 $6.00 $6.00 $11.10 n.a.
Citizens Financial Group   (CFG) Morgan Stanley/ Goldman Sachs 140.00 $23.00 $25.00 $3,360.00 n.a.
Cyber-Ark Software (CYBR) J.P. Morgan/ Deutsche Bank Securities/ Barclays 5.36 $13.00 $15.00 $75.04 n.a.
Eyegate Pharmaceuticals   (EYEG) Aegis Capital Corp 1.92 $12.00 $14.00 $25.00 n.a.
Great Basin Scientific  (GBSN)(u) Dawson James Securities, Inc. 2.50 $6.00 $7.00 $16.25 n.a.
Grupo Aval Acciones Y Valores S.A. (AVAL) J.P. Morgan/ Goldman Sachs 73.53 $14.96 $14.96 $1,099.99 n.a.
Harmony Merger (HRMNU) (u) Cantor Fitzgerald & Co. 10.00 $10.00 $10.00 $100.00 n.a.
ProQR Therapeutics B.V.  (TBA) Leerink Partners/ Deutsche Bank Securities 6.25 $11.00 $13.00 $75.00 n.a.
Smart & Final Stores (SFS) Credit Suisse/ Morgan Stanley/ Deutsche Bank Securities 13.45 $12.00 $14.00 $174.85 n.a.
Travelport Worldwide LTD (TVPT) Morgan Stanley/ UBS Securities/ Credit Suisse/ Deutsche Bank Securities 30.00 $14.00 $16.00 $450.00 n.a.
Vitae Pharmaceuticals   (VTAE) Stifel/ BMO Capital Markets 5.00 $11.00 $13.00 $60.00 n.a.
             
IPOs Priced Lead Shares Amount Offer Close %
Week of Sept. 8, 2014 Manager(s) Offered Raised Price 9/15/14 Change
ReWalk Robotics (RWLK) Barclays/ Jefferies 3.00 $36.00 $12.00 $25.60 113.33%
Affimed Therapeutics B.V. (AFMD) Jefferies/ Leerink Partners/ BMO Capital Markets 8.00 $56.00 $7.00 $5.76 -17.71%

The IPO Buzz: Showtime for Alibaba

The moment of truth will come on Friday morning, Sept. 19, when Alibaba is expected to start trading on the New York Stock Exchange.
 
The Alibaba offering – estimated at $20 billion – would be the largest IPO to come to market in the United States, according to the SEC filings. It would top the Visa (V) IPO of March 2008, when Visa sold 406 million shares at $44 each to raise $17.9 billion.
 
Alibaba by the Numbers
Here is what we know from the amendment to the prospectus:
The number of shares being offered: 320.1 million American Depositary Shares. Each ADS represents one ordinary share.
*The company will offer about 123.1 million ADS and selling shareholders will offer about 197 million ADS.
**Note: Yahoo will offer about 121.7 million ADS. Yahoo will own about 401.8 million ADS after the IPO.
 
The offering price: US$60 to US$66 per share (subject to change)
 
The amount expected to be raised: About US$20.2 billion, based on the mid-point of its price range
 
The number of shares outstanding after the offering:
2,465.0 million ADS
 
Market capitalization: $155.3 billion, based on the mid-point of its price range
 
The bankers: Six joint-lead managers – Credit Suisse, Deutsche Bank, Goldman Sachs, JPMorgan, Morgan Stanley and Citi;
14 co-managers (all listed on the cover of the prospectus) and 15 other underwriters (Complete list on page 310 of the prospectus, found here.)
 
The expected pricing date: Thursday, Sept. 18, to trade on the New York Stock Exchange on Friday morning, Sept. 19.
 
Visa’s Report Card
Passing note of interest: The Visa offering was a winner from the get-go. After Visa was priced at $44 per share, the IPO opened for trading on March 19, 2008, at $59.50, sold as high as $66 and closed its opening day at $56.50, UP 28.4 percent from its initial offering price. Visa closed on Friday, Sept. 5, 2014, at $214.21 – UP 279.1 per cent from its first day’s close.
 
Analysts still like the stock.
 
Research services report about 30 analysts rate Visa as a “Buy” to a “Strong Buy” with a mean average price target of $250 per share.
 
Since Alibaba filed to go public on May 6, 2014, the IPO parade has never stopped.
 
The calendar has produced 91 IPOs from May 6 to date. As of the close on Friday, Sept. 5th, a total of 68 IPOs were in the winner’s circle and 23 were losers; the average gain was 29.5 percent. Over that same time, the S&P 500 Index has gained 7.5 percent.
 
 
On the Medical Frontier
Turning to this week, the calendar has two offerings: Affimed Therapeutics and ReWalk Robotics.
 
Affimed Therapeutics (AFMD – proposed) is based in Heidelberg, Germany. This is a clinical-stage biopharmaceutical company focusing on the discovery and development of highly targeted cancer immunotherapies. The company’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The offering is expected to be priced on Thursday evening, Sept. 11, and to trade on Friday morning, Sept. 12. (For more information, please click here: Affimed Therapeutics)
 
ReWalk Robotics (RWLK – proposed) is an Israeli medical device company. ReWalk is developing exoskeletons that allow wheelchair-bound individuals to stand and walk. The offering is expected to be priced on Thursday evening, Sept. 11, and to trade on Friday morning, Sept. 12. (For more information, please click here: ReWalk Robotics)
 
This time next week, it’s showtime for Alibaba.
 
Stay tuned.
 
Disclosure: Neither the author nor anyone else on the IPOScoop.com staff has a position in any stocks mentioned, nor do we trade or invest in IPOs. The author and IPOScoop.com staff do not issue advice, recommendations or opinions.
 

IPO Traffic: Week Ending Sept. 5, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
EndoStim (STIM) Wedbush PacGrow Life Sciences       $40.25 n.a.
Upland Software (UPLD) William Blair/ Raymond James       $50.00 n.a.
Neff Corporation (NEFF) Morgan Stanley/ Jefferies/ Piper Jaffray     $100.00 n.a.
n.a. (not available)            
             
Postponed            
None            
             
Withdrawn            
None            
             
New Terms            
Affimed Therapeutics B.V. (AFMD) Jefferies/ Leerink Partners/ BMO Capital Markets 6.25 $11.00 $13.00 $75.00 2-Stars
Alibaba Group Holding  (BABA) Credit Suisse/ Deutsche Bank Securities/ Goldman Sachs/ J.P. Morgan/ Morgan Stanley/ Citi 320.10 $60.00 $66.00 $20,166.37 n.a.
Civitas Solutions  (CIVI) Barclays/ Jefferies/ BofA Merrill Lynch/ UBS Investment Bank 11.70 $20.00 $23.00 $251.55 n.a.
Foamix Ltd.   (FOMX) Barclays/ Cowen and Company 5.91 $10.00 $12.00 $65.00 n.a.
GWG Holdings (GWGH) Newport Coast Securities/ Axiom Capital Management/ Newbridge Securities 1.25 $11.50 $13.50 $15.63 n.a.
Product Shipping Limited   (PROS) Morgan Stanley       $100.00 n.a.
rEVO Biologics (RBIO) Piper Jaffray/ Guggenheim Securities 3.60 $13.00 $15.00 $50.40 1-Star
Tokai Pharmaceuticals  (TKAI) BMO Capital Markets/ Stifel/ William Blair 5.40 $13.00 $15.00 $75.60 n.a.
Viking Therapeutics (VKTX) Oppenheimer/ Roth Capital Partners 5.00 $10.00 $12.00 $55.00 n.a.
             
IPOs Priced Lead Shares Amount Offer Close %
Week of Sept. 1, 2014 Manager(s) Offered Raised Price 9/5/14 Change
None            

The IPO Buzz: Restocking the IPO Shelves

Hold on. There’s more.
 
On top of this traffic, countless other companies filed amendments updating their financials for the three months ended June 30, 2014. Note: People just don’t incur those enormous legal and accounting fees to file amendments, which can total over a million dollars, if they aren’t planning on jumping on the calendar in the near future.
 
Walk Like A Robot
Three companies filed amendments updating their proposed pricing terms and one became the first IPO on September’s calendar. That was ReWalk Robotics (RWLK – proposed), an Israeli medical device company. ReWalk is developing exoskeletons that allow wheelchair-bound individuals to stand and walk. The offering is expected to be priced on Thursday evening, Sept. 11, and to trade on Friday morning, Sept. 12. (For more information, please click here: ReWalk Robotics). There’s still more.   
 
The Dow Jones Industrial Average and the S&P 500 Index hit new record closing highs this past week and the NASDAQ Composite Index cruised to a 14-year high. Note: You don’t have an IPO market without the wind of a bull market at its back.
 
Ringside Seat
And finally the new-issues market has its own three-ring circus coming to town. It is the Alibaba Group Holdings (BABA – proposed) IPO. (For more information, please click here: Alibaba Group Holdings)
 
Guess what? On Thursday, Aug. 28, 2014, Alibaba filed an amendment updating its financials.
 
For the three months ended June 30, 2014, Alibaba reported a net income of RMB12.4 billion (US$1.99 billion), up from RMB4.4 billion, or up 179 percent, from the same period of a year ago. Alibaba reported revenues of RMB15.8 billion (US$2.54 billion), up from RMB10.8 billion, or up 43.6 percent, from the same period of a year ago.
 
The media reaction to that filing was like tossing kerosene on a roaring fire. That set the stage for the next shoe to drop in the Alibaba drama: the filing with Alibaba’s expected pricing terms. Only then will a trading date be announced. The gossip has the filing date as Tuesday, Sept. 2. If it happens, just wait for the media blitz.
 
Stay tuned.
 
Disclosure: Neither the author nor anyone else on the IPOScoop.com staff has a position in any stocks mentioned, nor do we trade or invest in IPOs. The author and IPOScoop.com staff do not issue advice, recommendations or opinions.
 
 

IPO Traffic: Weeks Ending Aug. 22 & 29, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
Axalta Coating Systems Ltd   (TBA) Citigroup/ Goldman Sachs/ Deutsche Bank Securities/ J.P. Morgan/ BofA Merrill Lynch/ Barclays/ Credit Suisse/ Morgan Stanley $100.00 n.a.
Calithera Biosciences  (CALA) Citigroup/ Leerink Partners/ Wells Fargo Securities/ JMP Securities $80.00 n.a.
Civitas Therapeutics (CVTS) J.P. Morgan/ BofA Merrill Lynch       $86.25 n.a.
CONE Midstream Partners LP  (CNNX) Wells Fargo Securities/ BofA Merrill Lynch/ Baird     $350.00 n.a.
Dermira  (DERM) Citigroup/ Leerink Partners       $75.00 n.a.
Enovation Controls (ENOV) Morgan Stanley/ UBS Securities       $100.00 n.a.
Great Western Bancorp (GWB) Deutsche Bank Securities/ BofA Merrill Lynch     $100.00 n.a.
HubSpot (HUBS) Morgan Stanley/ J.P. Morgan/ UBS Securitie     $100.00 n.a.
Hydra Industries Acquisition  (HDRAU) (u) UBS Investment Bank 10.00 $10.00 $10.00 $100.00 n.a.
Jaguar Animal Health  (JAGX) BMO Capital Markets/ Guggenheim Securities     $70.00 n.a.
LendingClub  (TBA) Morgan Stanley/ Goldman Sachs/ Citigroup     $500.00 n.a.
Medley Management  (MDLY) Goldman Sachs/ Credit Suisse       $150.00 n.a.
NeuroSigma (NSIG) Jefferies       $50.00 n.a.
Paramount Group  (PGRE) BofA Merrill Lynch/ Morgan Stanley/ Wells Fargo Securities   $100.00 n.a.
Rhythm Holding  (RYTM) Citigroup/ Cowen and Company       $86.25 n.a.
STORE Capital (STRE) Goldman Sachs/ Credit Suisse/ Morgan Stanley     $500.00 n.a.
USD Partners LP  (USDP ) Citigroup/ Barclays/ Credit Suisse/ BofA Merrill Lynch   $150.00 n.a.
Veritex Holdings  (VBTX) Sandler ONeill + Partners/ Stephens       $40.00 n.a.
Vivint Solar  (VSLR) Goldman Sachs/ BofA Merrill Lynch/ Credit Suisse   $200.00 n.a.
n.a. (not available)            
             
Postponed            
none            
             
Withdrawn            
Southeastern Grocers  (SEG) Citigroup/ Credit Suisse/ Deutsche Bank Securities/ William Blair/ Wells Fargo Securities $500.00 n.a.
             
New Terms            
ATD Corporation (ATD) BofA Merrill Lynch/ Deutsche Bank Securities/ Goldman Sachs/ Barclays/ J.P. Morgan/ UBS Investment Bank $100.00 n.a.
Capnia  (CAPNU) Maxim Group LLC 1.70 $5.00 $5.00 $8.50 1-Star
Diplomat Pharmacy  (DPLO) Credit Suisse/ Morgan Stanley/ J.P. Morgan/ Wells Fargo Securities/ William Blair/ Leerink Partners $100.00 n.a.
ReWalk Robotics (RWLK) Barclays/ Jefferies 3.35 $14.00 $16.00 $50.25 n.a.
Syndax Pharmaceuticals (SNDX) Deutsche Bank Securities/ Jefferies 4.30 $13.00 $15.00 $60.20 1-Star
             
IPOs Priced Lead Shares Amount Offer Close %
Week of Aug. 18 & Aug. 25, 2014 Manager(s) Offered Raised Price 8/29/14 Change
Sino Mercury Acquisition (SMACU) (u) Cantor Fitzgerald & Co. 4.00 $40.00 $10.00 $10.04 0.40%
             

The IPO Buzz: Alibaba Days and Nights

The latest scuttlebutt: Expect Alibaba to file its pricing terms on Tuesday, Sept. 2; launch its road show and price its IPO at $25 per share on or about Tuesday, Sept. 16. There’s talk that the deal will raise $20 billion. If all this is true, then the size of the offering would be 800 million American Depositary Shares. The back story: Bankers reportedly want to get the deal out the door ahead of the Jewish holidays.
 
Hold on. There was more scuttlebutt.
 
Bankers are said to be gearing up for a big September IPO market and the technology sector is in play. Of course, the multibillion-dollar Alibaba offering would tip the scales to size and technology.
 
Just One Word: Plastic
It’s hard to imagine most transactions in modern life without plastic – yes, that card in your wallet or the one connected to your smartphone.
 
The largest initial public offering in the U.S. capital markets was the 2008 Visa (V) IPO, according to the U.S. Securities and Exchange Commission filings. On March 18, Visa offered 406 million shares at $44 each to raise $17.9 billion. The IPO closed its opening day at $56.50, UP 28.4 percent from its initial offering price.
 
Fast forward to Friday, Aug. 15, 2014, Visa closed at $210.19, UP 377.8 percent from its initial offering price and UP 272 percent from its first day’s close.
 
Note: Investment research providers say that about 33 analysts follow Visa. The current rating on the stock ranges from a “Buy” to a “Strong Buy” with a mean price target of $250.
 
Google’s 10th Birthday
It was 10 years ago today, on Aug. 18, 2004, that the Google (GOOGL) IPO was priced. Google came to market with all the fanfare of a three-ring circus, like Alibaba. It was the talk of the town. Google lived up to all the hype – then and now.
 
Google offered 19.6 million shares of Class A common stock at $85 each to raise $1.67 billion. (That size ranks Google as No. 62 on a list of 102 blockbuster IPOs that raised $1 billion or more in the U.S. capital markets.)
 
Now here is where it gets complicated.
 
On April 3, 2014, Google did what it called a “2-for-1 stock split.” In reality, it was a stock distribution of a new class of non-voting common stock. The shareholders of Class A common stock (GOOGL) received 0.998 share of Class C common stock (GOOG) for each share of Class A common stock held. That made the Google IPO’s adjusted initial offering price $42.54 per share. The IPO closed its opening day at $100.34 ($50.22 adjusted), UP 18 percent from its initial offering price.
 
Fast forward to Friday, Aug. 15, 2014: Google’s old Class A common stock closed at $583.71 per share and its new Class C common stock closed at $573.48 per share for a combined worth of $1,157.19, UP 1,261.4 percent from its initial offering price and UP 1,053.3 percent from its first day’s close.
   
Note: Investment research providers say that about 47 analysts follow Google. The current rating on the Class A common stock is a “Buy” with a mean price target of $672.
 
Looking into the week of Aug. 25, 2014, the calendar remains “clean and green.” Vacation time is arriving in the land of IPOs and we will not be publishing next week. We will be back for the week of Sept. 2, 2014.
 
The staff of IPOScoop.com wishes everybody a wonderful late- summer siesta and a great Labor Day holiday weekend.
 
Stay tuned.
 
Disclosure: Neither the author nor anyone else on the IPOScoop.com staff has a position in any stocks mentioned, nor do we trade or invest in IPOs. The author and IPOScoop.com staff do not issue advice, recommendations or opinions.

IPO Traffic: Week Ending Aug. 15, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
Adama Agricultural Solutions Ltd.  (TBA) Goldman Sachs/ BofA Merrill Lynch       $300.00 n.a.
AR Capital Acquisition   (ARCAU) (u) Citigroup 30.00 $10.00 $10.00 $300.00 n.a.
Foamix Ltd.   (FOMX) Barclays/ Cowen and Company       $74.75 n.a.
Forward Pharma A/S  (FWP) Leerink Partners       $200.00 n.a.
Product Shipping Limited   (TBA) Morgan Stanley       $100.00 n.a.
ProQR Therapeutics B.V.  (TBA) Leerink Partners/ Deutsche Bank Securities     $75.00 n.a.
Second Sight Medical Products  (EYES) MDB Capital Group, LLC 3.50 $9.00 $9.00 $31.50 n.a.
Tokai Pharmaceuticals  (TKAI) BMO Capital Markets/ Stifel/ William Blair     $75.00 n.a.
Vitae Pharmaceuticals   (VTAE) Stifel/ BMO Capital Markets       $55.00 n.a.
Wayfair  (W) Goldman Sachs/ BofA Merrill Lynch/ Citigroup     $350.00 n.a.
n.a. (not available)            
u (unit offering)            
             
Postponed            
Capnia  (CAPNU) Maxim Group LLC 2.67 $6.50 $8.50 $20.00 1-Star
             
Withdrawn            
GeNO LLC (GNO) Jefferies/ Stifel       $50.00 n.a.
             
New Terms            
GWG Holdings (GWGH) Newport Coast Securities 1.00 $11.50 $13.50 $12.50 n.a.
             
IPOs Priced Lead Shares Amount Offer Close %
Week of Aug. 11, 2014 Manager(s) Offered Raised Price 8/15/14 Change
Otonomy (OTIC) J.P. Morgan/ BofA Merrill Lynch 6.25 $100.00 $16.00 $16.20 1.25%
C1 Financial  (BNK) Keefe, Bruyette & Woods (A Stifel Company)/ Raymond James 2.63 $44.74 $17.00 $16.90 -0.59%
             
             

The IPO Buzz: IPO Train’s Late Summer Run

August’s calendar has been a struggle. To date, 11 IPOs have been priced, according to the U.S. Securities and Exchange Commission filings. Of that number, investor demand was so lackluster that five were priced below their original filing ranges. Four were priced within range and two came to market after they were priced above range.
 
That’s the bad news.
 
Now for the good news: Bankers mostly got the prices right. Seven of the 11 IPOs closed their opening day in the winner’s circle, two did not, and the other two finished unchanged. The average gain for all 11 was 11.8 percent. And thanks to the stock market’s rebound from recent selloffs with Friday’s sharp rally, the major U.S. stock indexes finished the week with modest gains. The NASDAQ Composite Index gained 0.4 percent for the week and the S&P 500 rose 0.3 percent, while the Dow Jones Industrial Average advanced 0.4 percent.
 
This sets the stage for mid-August.
 
The IPO calendar lists five deals this week. Bankers expect to raise $240 million. That’s not much traffic, but vacation time is just around the corner.
 
One deal is a carryover from past weeks; two are small-cap offerings looking to raise $20 million each, and the other two are coming from the banking and pharmaceutical sectors.
 
Money Under the Sun
C1 Financial (BNK  – proposed) operates 28 banking centers and one loan production office on the West Coast of Florida and in Miami-Dade and Orange Counties. The bank caters to entrepreneurs and their families, noting that the “C1” in its name stands for Clients 1st and Community 1st, according to its website. C1 Financial believes it is the 20th– largest bank in the state of Florida by assets and the 17th largest by equity. C1 Financial also says it is one of the fastest-growing banks in the country when measured by asset growth. It assets increased to $1.4 billion on March 31, 2014, from $260 million on Dec. 31, 2009.
(For more information, please click here: C1 Financial)
 
All Ears
Otonomy (OTIC – proposed) is a clinical-stage biopharmaceutical company focusing on the development and commercialization of innovative therapeutics to treat diseases and disorders of the ear. The company’s lead product candidate, AuriPro, is a sustained-exposure antibiotic. Otonomy has recently completed two identical Phase 3 clinical trials in 532 pediatric patients with middle ear effusion, or fluid, at the time of tympanostomy tube placement (TTP) surgery.
(For more information, please click here: Otonomy)
 
Looking into the week of Aug. 18, 2014, the calendar is “clean and green.” So vacation time is arriving in the land of IPOs.
 
Stay tuned.
 
Disclosure: Neither the author nor anyone else on the IPOScoop.com staff has a position in any stocks mentioned, nor do we trade or invest in IPOs. The author and IPOScoop.com staff do not issue advice, recommendations or opinions.